BRPI0409977A - derivados de aminopropanol como moduladores de receptores esfingosina-1-fosfato - Google Patents
derivados de aminopropanol como moduladores de receptores esfingosina-1-fosfatoInfo
- Publication number
- BRPI0409977A BRPI0409977A BRPI0409977-0A BRPI0409977A BRPI0409977A BR PI0409977 A BRPI0409977 A BR PI0409977A BR PI0409977 A BRPI0409977 A BR PI0409977A BR PI0409977 A BRPI0409977 A BR PI0409977A
- Authority
- BR
- Brazil
- Prior art keywords
- sphingosine
- receptor modulators
- phosphate receptor
- aminopropanol derivatives
- aminopropanol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/141—Esters of phosphorous acids
- C07F9/1414—Esters of phosphorous acids with arylalkanols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
- C07F9/6541—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Abstract
"DERIVADOS DE AMINOPROPANOL COMO MODULADORES DE RECEPTORES ESFINGOSINA-1-FOSFATO". A invenção refere-se a compostos da fórmula (I) nos quais X, a, b, R~ 1~, R~ 2~, R~ 3~, R~ 4~ e R~ 5~ são como definidos no relatório descritivo, processos para sua produção, seus usos, e composições farmacêuticas que os contêm.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0309946 | 2003-04-30 | ||
GB0329494A GB0329494D0 (en) | 2003-12-19 | 2003-12-19 | Organic compounds |
GB0329501A GB0329501D0 (en) | 2003-12-19 | 2003-12-19 | Organic compounds |
PCT/EP2004/004572 WO2004096757A1 (en) | 2003-04-30 | 2004-04-29 | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0409977A true BRPI0409977A (pt) | 2006-05-09 |
Family
ID=33424536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0409977-0A BRPI0409977A (pt) | 2003-04-30 | 2004-04-29 | derivados de aminopropanol como moduladores de receptores esfingosina-1-fosfato |
Country Status (10)
Country | Link |
---|---|
US (1) | US7825260B2 (pt) |
EP (1) | EP1622866B1 (pt) |
JP (1) | JP4638410B2 (pt) |
CN (1) | CN1809531B (pt) |
AU (1) | AU2004234067B2 (pt) |
BR (1) | BRPI0409977A (pt) |
CA (1) | CA2523677A1 (pt) |
ES (1) | ES2392167T3 (pt) |
MX (1) | MXPA05011597A (pt) |
WO (1) | WO2004096757A1 (pt) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4505449B2 (ja) * | 2003-02-11 | 2010-07-21 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 新規二環式化合物および組成物 |
US7399765B2 (en) * | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
US7638637B2 (en) | 2003-11-03 | 2009-12-29 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
GB0411929D0 (en) * | 2004-05-27 | 2004-06-30 | Novartis Ag | Organic compounds |
JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | S1p受容体結合能を有する化合物およびその用途 |
MX2007000564A (es) * | 2004-07-16 | 2007-03-30 | Kyorin Seiyaku Kk | Metodo para utilizar efectivamente medicamentos referentes a la prevencion de efectos secundarios. |
EP1781595A1 (en) | 2004-08-13 | 2007-05-09 | Praecis Pharmaceuticals Inc. | Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity |
PL1806338T3 (pl) | 2004-10-12 | 2016-07-29 | Kyorin Seiyaku Kk | Sposób wytwarzania chlorowodorku 2-amino-2-[2-[4-(3-benzyloksyfenylotio)-2-chlorofenyio]etylo]-1,3-propanodioiu i jego hydratów oraz produkty pośrednie w ich wytwarzaniu |
EP1827606A2 (en) | 2004-12-06 | 2007-09-05 | University Of Virginia Patent Foundation | Aryl amide sphingosine 1-phosphate analogs |
GB0504544D0 (en) * | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
EP2332909B1 (en) | 2005-04-13 | 2014-10-15 | Astex Therapeutics Limited | Hydroxybenzamide derivatives and their use as inhibitors of hsp90 |
WO2007043433A1 (ja) * | 2005-10-07 | 2007-04-19 | Kyorin Pharmaceutical Co., Ltd. | 2-アミノ-1,3-プロパンジオール誘導体を有効成分とする肝臓疾患治療剤および肝臓疾患治療方法 |
KR100773765B1 (ko) | 2005-11-24 | 2007-11-12 | 재단법인서울대학교산학협력재단 | 개선된 스핑고신 유사체의 제조 방법 |
EP1986623A2 (en) | 2006-01-27 | 2008-11-05 | University Of Virginia Patent Foundation | Method for treatment of neuropathic pain |
TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
WO2007092638A1 (en) * | 2006-02-09 | 2007-08-16 | University Of Virginia Patent Foundation | Bicyclic sphingosine 1-phosphate analogs |
US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
US8097644B2 (en) * | 2006-03-28 | 2012-01-17 | Allergan, Inc. | Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist |
MX352516B (es) | 2006-07-05 | 2017-04-06 | Fibrotech Therapeutics Pty Ltd | Compuestos terapeuticos. |
MY146775A (en) * | 2006-08-08 | 2012-09-28 | Kyorin Seiyaku Kk | Amino alcohol derivative and immunosuppressive agent having same as an active ingredient |
DK2058317T3 (da) * | 2006-08-08 | 2014-01-06 | Kyorin Seiyaku Kk | Aminophosphorsyreesterderivat og S1P receptormodulator indeholdende samme som aktiv ingrediens |
EP2073802A1 (en) | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
EP2073804B1 (en) | 2006-10-12 | 2017-09-13 | Astex Therapeutics Limited | Hydroxy-substituted benzoic acid amide compounds for use in the treatment of pain |
WO2008044027A2 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical compounds having hsp90 inhibitory or modulating activity |
WO2008064337A2 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
JP2010510250A (ja) * | 2006-11-21 | 2010-04-02 | ユニバーシティ オブ バージニア パテント ファンデーション | スフィンゴシン=1−燐酸受容体アゴニスト活性を有するヒドリンダンアナログ |
JP2010510249A (ja) * | 2006-11-21 | 2010-04-02 | ユニバーシティ オブ バージニア パテント ファンデーション | スフィンゴシン=1−燐酸アゴニスト活性を有するテトラリンアナログ |
JO2686B1 (en) * | 2007-04-19 | 2013-03-03 | جلاكسو جروب ليمتد | Vehicles |
WO2009023854A1 (en) * | 2007-08-15 | 2009-02-19 | University Of Virginia Patent Foundation | Bicyclic sphingosine 1-phosphate analogs |
BRPI0817448A2 (pt) * | 2007-09-28 | 2015-06-16 | Univ Virginia Patent Found | Composto, composição farmacêutica, método para prevenção ou tratamento de uma condição patológica ou sintoma em um mamífero, uso de um composto, e, kit |
TW200946105A (en) | 2008-02-07 | 2009-11-16 | Kyorin Seiyaku Kk | Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient |
GB0806527D0 (en) | 2008-04-11 | 2008-05-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
TW201000099A (en) * | 2008-06-20 | 2010-01-01 | Amgen Inc | S1P1 receptor agonists and use thereof |
MX2011000211A (es) * | 2008-07-15 | 2011-03-03 | Sanofi Aventis | Oxazolopirimidinas como agonistas del receptor edg-1. |
KR20190132565A (ko) * | 2008-07-23 | 2019-11-27 | 아레나 파마슈티칼스, 인크. | 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[b]인돌-3-일)아세트산 유도체 |
CN105816453B (zh) | 2008-08-27 | 2021-03-05 | 艾尼纳制药公司 | 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物 |
CN102574843B (zh) * | 2009-10-22 | 2015-06-17 | 法博太科制药有限公司 | 抗纤维化剂的稠环类似物 |
WO2011050054A2 (en) * | 2009-10-23 | 2011-04-28 | Allergan, Inc. | Coumarin compounds as receptor modulators with therapeutic utility |
JP5841067B2 (ja) * | 2010-01-14 | 2016-01-06 | サノフイ | 2,5−置換されたオキサゾロピリミジン環を有するカルボン酸誘導体 |
MX2012007837A (es) * | 2010-01-14 | 2012-07-30 | Sanofi Sa | Derivados de oxazolopirimidina 2, 5 - sustituidos. |
AR079884A1 (es) * | 2010-01-14 | 2012-02-29 | Sanofi Aventis | Derivados de acido carboxilico heterociclicos que comprenden un anillo de oxazolopirimidina 2,5-sustituida |
ES2937386T3 (es) | 2010-01-27 | 2023-03-28 | Arena Pharm Inc | Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo |
CA2789480A1 (en) | 2010-03-03 | 2011-09-09 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
CN102260178A (zh) * | 2010-05-25 | 2011-11-30 | 中国医学科学院药物研究所 | 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途 |
SG194184A1 (en) * | 2011-04-14 | 2013-11-29 | Allergan Inc | Phenyl bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators |
CA2853221A1 (en) * | 2011-10-24 | 2013-05-02 | Tohru Yamashita | Bicyclic compound |
JP6194306B2 (ja) | 2012-04-23 | 2017-09-06 | 田辺三菱製薬株式会社 | アミン化合物及びその医薬用途 |
CN105026360B (zh) * | 2013-01-29 | 2017-08-25 | 比奥根Ma公司 | S1p调节剂 |
CN105017034B (zh) * | 2014-04-17 | 2019-02-15 | 中国科学院上海药物研究所 | 氨基醇类化合物、其制备方法、包含此类化合物的药物组合物及其用途 |
WO2016112075A1 (en) | 2015-01-06 | 2016-07-14 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
SI3310760T1 (sl) | 2015-06-22 | 2023-02-28 | Arena Pharmaceuticals, Inc. | Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1 |
CN110546133A (zh) | 2017-02-03 | 2019-12-06 | 塞尔塔治疗有限公司 | 抗纤维化化合物 |
AU2018222747A1 (en) | 2017-02-16 | 2019-09-05 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
CA3053418A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
KR102292989B1 (ko) | 2017-03-29 | 2021-08-26 | 재단법인 아산사회복지재단 | S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물 |
CN112955431A (zh) | 2018-09-06 | 2021-06-11 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001277731A1 (en) | 2000-08-09 | 2002-02-18 | Welfide Corporation | Fused bicyclic amide compounds and medicinal use thereof |
CA2442178A1 (en) * | 2001-03-26 | 2002-10-03 | Novartis Ag | 2-amino-propanol derivatives |
JP2002316985A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
GB0405289D0 (en) * | 2004-03-09 | 2004-04-21 | Novartis Ag | Organic compounds |
GB0411929D0 (en) * | 2004-05-27 | 2004-06-30 | Novartis Ag | Organic compounds |
-
2004
- 2004-04-29 EP EP04730225A patent/EP1622866B1/en not_active Expired - Lifetime
- 2004-04-29 ES ES04730225T patent/ES2392167T3/es not_active Expired - Lifetime
- 2004-04-29 MX MXPA05011597A patent/MXPA05011597A/es active IP Right Grant
- 2004-04-29 WO PCT/EP2004/004572 patent/WO2004096757A1/en active Search and Examination
- 2004-04-29 AU AU2004234067A patent/AU2004234067B2/en not_active Ceased
- 2004-04-29 JP JP2006505329A patent/JP4638410B2/ja not_active Expired - Fee Related
- 2004-04-29 BR BRPI0409977-0A patent/BRPI0409977A/pt not_active IP Right Cessation
- 2004-04-29 CN CN2004800171527A patent/CN1809531B/zh not_active Expired - Fee Related
- 2004-04-29 CA CA002523677A patent/CA2523677A1/en not_active Abandoned
- 2004-04-29 US US10/554,557 patent/US7825260B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
MXPA05011597A (es) | 2005-12-15 |
WO2004096757A8 (en) | 2005-01-27 |
ES2392167T3 (es) | 2012-12-05 |
AU2004234067B2 (en) | 2008-02-28 |
CN1809531B (zh) | 2010-05-26 |
EP1622866A1 (en) | 2006-02-08 |
US7825260B2 (en) | 2010-11-02 |
US20060211656A1 (en) | 2006-09-21 |
AU2004234067A1 (en) | 2004-11-11 |
CA2523677A1 (en) | 2004-11-11 |
EP1622866B1 (en) | 2012-07-25 |
WO2004096757A1 (en) | 2004-11-11 |
JP2006524662A (ja) | 2006-11-02 |
CN1809531A (zh) | 2006-07-26 |
JP4638410B2 (ja) | 2011-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0409977A (pt) | derivados de aminopropanol como moduladores de receptores esfingosina-1-fosfato | |
BR122019010008B8 (pt) | derivados de pirimidina, seu uso, e composição e combinação farmacêuticas | |
BR0108678A (pt) | Novos compostos | |
BRPI0413860A (pt) | [1,8]naftiridin-2-onas e compostos relacionados para o tratamento de esquizofrenia | |
MX2009005461A (es) | N-oxidos de analogos de 4,5-epoxi-morfinano. | |
BR0208338A (pt) | Derivados de piridina | |
UY28186A1 (es) | N-arilheterociclos sustituidos, procedimientos para su preparación, y su empleo como medicamentos. | |
BR0312513A (pt) | Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos | |
BRPI0510453A (pt) | composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central | |
NO20061845L (no) | Fenyl-piperazinderivater som modulatorer for muskarine reseptorer | |
BRPI0512986A (pt) | novos derivados de hidantoìna | |
ECSP066914A (es) | FORMA CRISTALINA dd DEL CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN | |
SE0104140D0 (sv) | Novel Compounds | |
BRPI0512352A (pt) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas | |
ECSP088854A (es) | Moduladores bencimidazolicos de vr1 | |
BRPI0113162B8 (pt) | compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos | |
BRPI0511874A (pt) | derivados da pirrolopiridina | |
SE0401762D0 (sv) | Novel compounds | |
BRPI0413094A (pt) | derivados de quinolina e seu uso em terapia | |
CU23415B7 (es) | Derivados de 2,6- quinolinilo y 2,6- naftilo, procesos para su preparación y sus usos | |
NO20062824L (no) | 1,3-Difenylprop-2-en-1-on-avledete forbindelser, fremgangsmater for fremstilling derav, samt anvendelse av samme | |
SV2004001555A (es) | Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos | |
BRPI0417036A (pt) | novos derivados espiro-tricìclicos como moduladores de atividade de receptor quimiocina | |
ECSP045493A (es) | Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a | |
BRPI0409436A (pt) | compostos de 4-fenil-piperidina e a sua utilização como moduladores de receptores de opióides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |